SAB Biotherapeutics, Inc. Income Statement
SABS|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
SAB Biotherapeutics, Inc. reported $1M in revenue and $34M in net loss for FY2025. Revenue has declined at a 60.7% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $2.2M | $23.9M | $60.9M | $55.2M |
| SG&A Expense | $14.0M | $23.8M | $16.4M | $17.1M | $6.8M |
| R&D Expense | $30.3M | $16.5M | $36.4M | $57.2M | $27.9M |
| Operating Income | -$42.9M | -$38.1M | -$28.9M | -$13.4M | $20.6M |
| Interest Expense | - | - | $301.6K | $294.5K | $469.2K |
| Income Tax | $0 | $0 | $25.6K | $0 | $0 |
| Net Income | -$34.1M | -$42.2M | -$18.7M | -$17.1M | $20.1M |
| EPS (Basic) | -$3.68 | -$7.64 | -$4.31 | -$0.63 | $0.79 |
| EPS (Diluted) | -$3.68 | -$7.64 | -$4.31 | - | $0.74 |
| Shares Outstanding | 9.3M | 9.2M | 5.0M | 26.0M | 26.0M |
| Operating Margin | -3244.9% | -1700.6% | -121.0% | -22.0% | 37.2% |
| Profit Margin | -2579.0% | -1884.5% | -78.4% | -28.2% | 36.4% |